ライフサイエンスコーパス: anticancer drug

1 l malignancies, and are now on the market as anticancer 'drugs'.

2 resence of chlorambucil as a model template (anticancer drug).

3 nificantly improves the effectiveness of the anticancer drug.

4 i warrants further evaluation as a potential anticancer drug.

5 unds that shield ears and kidneys against an anticancer drug.

6 latform to identify both antiherpesviral and anticancer drugs.

7 lations that display distinct sensitivity to anticancer drugs.

8 cally identify therapeutic agents and screen anticancer drugs.

9 been widely applied for targeted delivery of anticancer drugs.

10 ical models to accelerate the development of anticancer drugs.

11 function and a promising lead for developing anticancer drugs.

12 reat potential for further optimization into anticancer drugs.

13 ophobic and amphipathic compounds, including anticancer drugs.

14 ght, may find use in the search for improved anticancer drugs.

15 sible for the efflux of an ample spectrum of anticancer drugs.

16 s in tumors or to decipher the mechanisms of anticancer drugs.

17 onal design of PAICS inhibitors as potential anticancer drugs.

18 a promising lead for the development of new anticancer drugs.

19 ic load should make tumors more sensitive to anticancer drugs.

20 es together with their response to 24 common anticancer drugs.

21 or inevitably acquire such when treated with anticancer drugs.

22 d numerous TFs whose activity interacts with anticancer drugs.

23 elopment and may represent novel targets for anticancer drugs.

24 lating compounds that represent the earliest anticancer drugs.

25 large storage space and release channels for anticancer drugs.

26 ibodies, an increasingly successful class of anticancer drugs.

27 ance and serves as a major target of several anticancer drugs.

28 ging evidence in favor of SMAPs as potential anticancer drugs.

29 ponsible for anticancer activity of platinum anticancer drugs.

30 inum-containing molecules are widely used as anticancer drugs.

31 rating 3D mechanical cues into screening for anticancer drugs.

32 g diagnostics as well as active targeting of anticancer drugs.

33 pplications as antimicrobial, antiviral, and anticancer drugs.

34 the development of heparanase inhibitors as anticancer drugs.

35 ce by cancer cells limit the use of platinum anticancer drugs.

36 tive target for the development of effective anticancer drugs.

37 icacy of clinically important Top2-targeting anticancer drugs.

38 ts to create the next generation of platinum anticancer drugs.

39 cell death is the therapeutic goal for most anticancer drugs.

40 g promising leads for the development of new anticancer drugs.

41 or development of efficient antimalarial and anticancer drugs.

42 ug loadings and co-delivery of two different anticancer drugs.

43 increasing the efficacy of a broad range of anticancer drugs.

44 st cancer cells as well as their response to anticancer drugs.

45 op2 engagement of DNA damage or poisoning by anticancer drugs.

46 ad for developing a new mechanistic class of anticancer drugs.

47 me and ultimately could impact the design of anticancer drugs.

48 sight into the future design of Ti(IV)-based anticancer drugs.

49 Fluoropyrimidines are frequently prescribed anticancer drugs.

50 ects significantly limit the applications of anticancer drugs.

51 ndant target for affinity-guided delivery of anticancer drugs.

52 uld often affect the response of patients to anticancer drugs.

53 isomerase II (topoII), a validated target of anticancer drugs.

54 peutic efficacies and reduce side effects of anticancer drugs.

55 novel and potentially safer topoII-targeted anticancer drugs.

56 lso enhance body elimination of non-targeted anticancer drugs.

57 able molecules such as renewable biofuels or anticancer drugs.

58 esistance in antibiotics, antimicrobials and anticancer drugs.

59 or several US FDA-approved and up-and-coming anticancer drugs.

60 r therapy response and screening preclinical anticancer drugs.

61 ecule PARP inhibitors have emerged as potent anticancer drugs.

62 r the development of novel antimicrobial and anticancer drugs.

63 8a might be a promising lead for developing anticancer drugs.

64 ng that paclitaxel and other clinically used anticancer drugs actively induce metastasis even while s

65 mor multidrug resistance (MDR) is to deliver anticancer drug along with P-glycoprotein (P-gp) inhibit

66 e currently considered promising targets for anticancer drugs, alternatively to the encoded protein.

67 Moreover, camptothecin (CPT) is used as the anticancer drug and modified into a dimer (CPT)2 -ss-Mal

68 th peptoid (PE2) can be used as carriers for anticancer drug and protein, where the peptoid modulated

69 etrial cancer cells have varied responses to anticancer drugs and cancer therapies.

70 stance calls for continuously developing new anticancer drugs and combination chemotherapy regimens.

71 Nearly all anticancer drugs and even novel immunotherapies, which r

72 useful information for design of G4-targeted anticancer drugs and fluorescent probes.

73 oxifen drug conjugates show promise as novel anticancer drugs and further preclinical and clinical ev

74 transporter that confers resistance to many anticancer drugs and plays a role in the disposition and

75 Cancer persister cells tolerate anticancer drugs and serve as the founders of acquired r

76 mechanisms of action of ruthenium(ii)-based anticancer drugs and the relationship between their chem

77 uld improve the translatability of potential anticancer drugs and treatments.

78 ted by coencapsulating doxorubicin (DOX) (an anticancer drug) and IR780 iodide (IR780) (an NIR-absorb

79 roenvironment stress, chemotherapy, targeted anticancer drugs, and even immunotherapy.

80 re two Food and Drug Administration-approved anticancer drugs, and proteasome is the drug target.

81 xpected proteins bound by diverse compounds (anticancer drugs, antibiotics).

82 , drugs affecting the cardiovascular system, anticancer drugs, antibiotics, antiviral and antifungal

83 Many new anticancer drugs approved over the past decade are "targ

84 Mutants sensitive to 5-fluorouracil, an anticancer drug are under-represented within the 305 pos

85 onable molecular variants for which approved anticancer drugs are available(1-3).

86 ly actionable variants for which no approved anticancer drugs are available.

87 Most of the FDA approved anticancer drugs are organic molecules, while metallodru

88 Platinum-based anticancer drugs are widely used as a first-line drug fo

89 the effects of three or more antibiotics or anticancer drugs at all doses based only on measurements

90 together, our data suggests key targets for anticancer drugs based on cellular genotypes and their s

91 ir of DNA damage produced by a redox-cycling anticancer drug, beta-lapachone (beta-lap).

92 d OAT1 degrades and unveiled a novel role of anticancer drugs bortezomib and carfilzomib in their reg

93 Anticancer drugs bortezomib and carfilzomib target the u

94 Despite recent structural insights, no anticancer drug bound to ABCG2 has been resolved, and th

95 Doxorubicin (Dox) is a highly effective anticancer drug but cause acute ventricular dysfunction,

96 Taxol (paclitaxel) is a very widely used anticancer drug, but its commercial sources mainly consi

97 ance brain delivery of ABCB1/ABCG2 substrate anticancer drugs, but its clinical applicability for con

98 TOP2 poisons are valuable and widely used anticancer drugs, but they are associated with the occur

99 ing cancer proteins are sufficient to screen anticancer drugs by an array-based SPRi technique with e

100 n enhancing and site-directing the effect of anticancer drugs by illumination, which initiates locali

101 livery system (DDS) to release two different anticancer drugs (caffeic acid and chlorambucil, 1 equiv

102 odytes nimmoniana is a rich source of potent anticancer drug camptothecin (CPT) whose biosynthetic pa

103 Alterations in renal clearance of anticancer drugs can affect the occurrence of toxicities

104 Activity of IP anticancer drugs can be further potentiated by encapsula

105 Due to the great potential expressed by an anticancer drug candidate previously reported by our gro

106 our findings suggest that 4o is a promising anticancer drug candidate that warrants further preclini

107 Among them, Ru-based anticancer drug candidates have become a central subject

108 n innovative framework for discovering novel anticancer drug candidates.

109 s of a patient undergoing treatment with the anticancer drug cisplatin were studied.

110 r of TRPV4, GSK1016790A, in combination with anticancer drug cisplatin, significantly reduced tumor g

111 tins are adducts of two chemically important anticancer drugs, cisplatin and arsenic trioxide, that h

112 vantages of applying nanocarriers to improve anticancer drug combination therapy, review the use of n

113 To maximize the therapeutic potential of anticancer drugs, combination therapies and multitarget

114 Conclusion Anticancer drug costs may change substantially after lau

115 Cisplatin, one of the most widely used anticancer drugs, crosslinks DNA and ultimately induces

116 We found that the binding of candidate anticancer drug, curaxin, to cellular DNA results in unc

117 lso compromised the inhibitory effect of the anticancer drug dasatinib on Src kinase oncogenic potent

118 onitoring of biointeraction occurred between anticancer drug, Daunorubicin (DNR), and DNA.

119 or effects, indicating their potential as an anticancer drug delivery system.

120 The development of anticancer drug delivery systems which retain or enhance

121 y, protected delivery of bioactive moieties, anticancer drug delivery systems, and theranostics (i.e.

122 localize to marrow could improve NP-mediated anticancer drug delivery to sites of bone metastasis, th

123 ocarriers can be utilized to further improve anticancer drug delivery without the need for prolonged

124 ation an unresolved obstacle to an effective anticancer drug delivery.

125 to reconcile long-standing paradoxes in the anticancer drug delivery.

126 g in vitro and potentially also for specific anticancer drug delivery.

127 ce and permeation-retention paradoxes in the anticancer-drug delivery.

128 icinal and biological interest, including as anticancer drugs designed to cleave intracellular biomol

129 somerase I may serve as a novel strategy for anticancer drug development.

130 and 'non-human' animal models in preclinical anticancer drug development.

131 ets for cholesterol-lowering medications and anticancer drug development.

132 on as important tools in cancer research and anticancer drug development.

133 ity of the proteasome as a viable target for anticancer drug development.

134 tinues to appeal as a strategy to exploit in anticancer drug development.

135 Not limited to anticancer drugs, diagnostic agents can also be achieved

136 th variable oxidation states hold promise in anticancer drug discovery and need further development.

137 A growing emphasis in anticancer drug discovery efforts has been on targeting

138 the cell cycle and are validated targets for anticancer drug discovery.

139 lls, endorsing their further exploration for anticancer drug discovery.

140 comment on the potential of this approach in anticancer drug discovery.

141 get agents is an emerging approach in modern anticancer drug discovery.

142 ell apoptosis showed that NWs loaded with an anticancer drug displayed long blood-circulation time an

143 We show that ZIF-8 crystals loaded with the anticancer drug doxorubicin (DOX) are efficient drug del

144 This system consists of GNPs conjugated to anticancer drug doxorubicin (Dox) by a pH-cleavable bond

145 rameworks (nCOFs) were first loaded with the anticancer drug Doxorubicin (Dox), coated with magnetic

146 ap the hydrophobic dye Nile Red (NR) and the anticancer drug doxorubicin (DOX).

147 rmeation, distribution, and retention of the anticancer drug doxorubicin in both cancerous and normal

148 Anthracycline anticancer drugs doxorubicin and aclarubicin have been u

149 The anticancer drug (doxorubicin (DOX))-treated cells show s

150 centrations of several analytes-including an anticancer drug (doxorubicin), several TDM-requiring ant

151 of quickly quantifying concentrations of the anticancer drug, doxorubicin (DOX).

152 ered at low doses, has emerged as a powerful anticancer drug due to both chemopreventive activity aga

153 e is an attractive target for antibiotic and anticancer drugs due to its essential role in the de nov

154 Anticancer drug efficacy has been tested on circulating

155 used to make cancer cells less resistant to anticancer drugs, especially in HCV-positive HCC patient

156 (III) complexes are promising candidates for anticancer drugs, especially the clinically studied inda

157 , as compared to an IC(50) = 120 muM for the anticancer drug etoposide] with excellent metabolic stab

158 ed to continuously monitor the effect of the anticancer drug fluorouracil (5-FU) on HCT116 cancer sph

159 sensor for the simultaneous determination of anticancer drug Flutamide (FLU) and antibiotic drug Nitr

160 tivation of RA signaling by all-trans RA, an anticancer drug for acute promyelocytic leukemia, blocke

161 is study suggest that 15a may be a potential anticancer drug for the treatment of GISTs and AML.

162 Cisplatin is the most commonly used anticancer drug for the treatment of testicular germ cel

163 To expand the repertoire of anticancer drugs for injection, acyl and oligo(lactic ac

164 icles, that increase the water solubility of anticancer drugs for injection.

165 I and III) trials supporting FDA approval of anticancer drugs from 1998 to 2018 were evaluated.

166 ophobic and amphipathic compounds, including anticancer drugs from cells.

167 s were used to synthesize catechol (a potent anticancer drug) from salicylic acid to inhibit lung, br

168 When given the anticancer drug gefitinib or the retroviral drug atazana

169 sor has been tested for immobilization of an anticancer drug gemcitabine (2',2'-difluoro-2'-deoxycyti

170 Our previous study showed that the anticancer drug Gleevec lowers Abeta levels through indi

171 cytotoxic molecules known, and their use as anticancer drugs has been successfully demonstrated by t

172 Taxol (paclitaxel), a plant-derived anticancer drug, has been among the most successful anti

173 high rate of relapse and resistance against anticancer drugs have been associated with a highly abno

174 Consequently anticancer drugs have been developed that target this pa

175 elson (Abl) kinase inhibitors, including the anticancer drug imatinib, as inhibitors of both SARS-CoV

176 l compound libraries for antiherpesviral and anticancer drugs.IMPORTANCE Epstein-Barr virus, which is

177 Many anticancer drugs in clinical use and under investigation

178 tubule assembly and disassembly include many anticancer drugs in clinical use.

179 posure in murine tumor models, versus parent anticancer drugs in conventional formulations.

180 ion, and to preclinically evaluate candidate anticancer drugs in living animals.

181 Precise control of in vivo transport of anticancer drugs in normal and cancerous tissues with en

182 us to analyze their relative sensitivity to anticancer drugs in vitro using a chemogram, similar to

183 e quest for discovery and development of new anticancer drugs, including antibody-drug conjugates as

184 omotes cancer cell susceptibility to various anticancer drugs, including docetaxel (microtubule stabi

185 ses the sensitivity of human cancer cells to anticancer drug-induced apoptosis.

186 new therapeutic strategy to protect against anticancer drug-induced peripheral neurotoxicity.

187 ll culture results indicative of synergistic anticancer drug interactions rarely translate clinically

188 veloped algorithm are capable of binding the anticancer drug irinotecan (CPT-11) with micromolar affi

189 uccessfully detected the abundance change of anticancer drug irinotecan and its metabolites inside sp

190 erform rapid absolute quantifications of the anticancer drug irinotecan in individual mammalian cance

191 16 colorectal cancer cells, treated with the anticancer drug Irinotecan under a series of time- and c

192 of action (MoA) for new and uncharacterized anticancer drugs is important for optimization of treatm

193 ed in pivotal trials supporting contemporary anticancer drugs is unknown.

194 Noscapine is a potential anticancer drug isolated from the opium poppy Papaver so

195 l mechanisms of cancer and in developing new anticancer drugs, it remains extremely challenging to cu

196 are associated with differential response to anticancer drugs, knowledge that may assist lung cancer

197 Ibrutinib is an anticancer drug known to modulate T-helper type 1 (Th1)/

198 some, has been associated with resistance to anticancer drugs, leading autophagy inhibition to be wid

199 Limiting out-of-pocket costs for expensive anticancer drugs like the IMiDs may improve access to or

200 o papers in Cell exploit C. elegans to infer anticancer drug mechanisms.

201 trial importance as the active moiety of the anticancer drug mipsagargin, currently in clinical trial

202 The anticancer drugs, mitomycin C (MIC(50) = 0.25 mug/ml) an

203 ate, an intermediate in the synthesis of the anticancer drug niraparib.

204 The Ru-based anticancer drug NKP-1339 was studied applying XANES (Cl

205 cer drug, has been among the most successful anticancer drugs of natural origin.

206 point-of-sale prices for orally administered anticancer drugs offered through Medicare Part D and out

207 To study the influence of an anticancer drug on the spatially resolved metabolites, s

208 Food and Drug Administration (FDA)-approved anticancer drugs or compounds currently in clinical deve

209 cy of nanoparticles as delivery vehicles for anticancer drugs or imaging agents.

210 translation of new insights into the use of anticancer drugs outside of their approved label, and cr

211 lecular variants, who are being treated with anticancer drugs outside of their approved label.

212 oids upon treatment with the clinically used anticancer drug oxaliplatin.

213 ctive precursor of the potent broad-spectrum anticancer drug paclitaxel (a.k.a. Taxol) that is stable

214 The anticancer drug paclitaxel (Taxol) exhibits paradoxical

215 nt member of this subfamily, metabolizes the anticancer drug paclitaxel, certain antidiabetic drugs,

216 ggressive CIPN model utilizing the frontline anticancer drug, paclitaxel (PTX).

217 In silico analysis identified 390 novel anticancer drug pairs belonging to 10 drug classes that

218 herein with the cell-specific release of the anticancer drug panobinostat.

219 increased the intracellular accumulation of anticancer drugs, particularly doxorubicin and [(3)H]-pa

220 DCs) containing diverse, clinically relevant anticancer drug payloads (docetaxel, cabazitaxel, and ge

221 sms are frequently used in antimicrobial and anticancer drugs, pesticides, herbicides or fungicides.

222 ncluding antimicrobial and antiviral agents, anticancer drugs, photodynamic therapy agents, radiother

223 In particular, romidepsin, an FDA-approved anticancer drug, potently inhibited tail regeneration wh

224 lated targeted drugs [A bacteria-synthesized anticancer drug (prodigiosin) and paclitaxel] using sing

225 ardize new therapeutic immunosuppressive and anticancer drugs protocols.

226 prehensive approach to designing combination anticancer drug regimens.

227 DNA-damaging anticancer drugs remain a part of metastatic melanoma th

228 Smo inhibitor vismodegib, a clinically used anticancer drug reported to distort smell perception in

229 ese results confirm that DNAJA1 is a hub for anticancer drug resistance and that DNAJA1 inhibition is

230 have an important role in the acquisition of anticancer drug resistance in a subset of human malignan

231 regulatory pathways and programs involved in anticancer drug resistance.

232 by stably enhanced stem cell generation and anticancer drug resistance.

233 resistance, further implicating cMET in the anticancer drug response.

234 and further characterized tumorigenesis and anticancer drug responses.

235 apid optical microarray imaging approach for anticancer drug screening at specific cancer protein-pro

236 device technology (cancer models) for use in anticancer drug screening.

237 Our results indicate that anticancer drug significantly affected the abundances of

238 nducive for the efficient delivery of NO and anticancer drugs, simultaneously.

239 hodology to locate spatially the presence of anticancer drug sites in metaphase chromosomes and cellu

240 A number of established and investigational anticancer drugs slow the religation step of DNA topoiso

241 ors for antibacterial activity and found the anticancer drug sorafenib as major hit that effectively

242 inic and include frontline antimicrobial and anticancer drugs such as erythromycin and doxorubicin.

243 -guided surgery, but also tailor the fate of anticancer drugs such as imatinib (IM) to the tumor site

244 of AH-7614 containing features found in many anticancer drugs suggests that a novel close chemical an

245 imprinted nanogels for the detection of the anticancer drug sunitinib were synthesized and character

246 on extracellularly, thereby enabling in situ anticancer drug synthesis and screening without the cata

247 th contactless conductivity detection of the anticancer drug tamoxifen as well as its metabolites.

248 Protein CK2 has gained much interest as an anticancer drug target in the past decade.

249 lls; however, this receptor is an attractive anticancer drug target owing to the overexpression of FR

250 e findings are important because GLUT6 is an anticancer drug target, and this study suggests that inh

251 n homoeostasis has made VCP/p97 an appealing anticancer drug target.

252 ell DNA-damage response and is an attractive anticancer drug target.

253 ng cell division, and as such, it is a broad anticancer drug target.

254 human AP endonuclease 1, which is as a valid anticancer drug target.

255 Anticancer drugs targeting TOP2 (TOP2 poisons) prevent r

256 Cancer cell mitochondria are promising anticancer drug targets because they control cell death

257 herapeutic agents, including next generation anticancer drug targets with amplified effectivity.

258 we reflect on the potential of Orai-STIMs as anticancer drug targets.

259 ese findings reveal a mechanism by which the anticancer drug temozolomide induces senescence and down

260 phenocopied by treatment with indisulam, an anticancer drug that functions through DCAF15 engagement

261 Cisplatin is a major anticancer drug that kills cancer cells by damaging thei

262 polymerase (PARP) inhibitors are a class of anticancer drugs that block the catalytic activity of PA

263 ctic acid) ester prodrugs widen the range of anticancer drugs that can be tested safely and effective

264 Treatment of carcinoma models with anticancer drugs that differ in their mechanism of actio

265 tment with sunitinib and erlotinib, approved anticancer drugs that inhibit AAK1 or GAK activity, or w

266 PK11007 may be a lead for anticancer drugs that target cells with nonfunctional p5

267 osts for a cohort of 24 patented, injectable anticancer drugs that were approved by the US Food and D

268 trast to cisplatin or the progenitor RAPTA-C anticancer drugs, the binuclear agents neither arrest sp

269 emonstrate that both types of Top2-targeting anticancer drugs, the catalytic inhibitor dexrazoxane (I

270 f various solute carriers to the toxicity of anticancer drugs, the contribution of these proteins to

271 the delivery of nucleoside analogues used in anticancer drug therapy.

272 In today's development of anticancer drugs, there is an enormous demand for sensit

273 due to reduction of intracellular levels of anticancer drugs through ATP-binding cassette (ABC) pump

274 r cells acquired resistance against multiple anticancer drugs, thus suggesting that ECRG2 mutations a

275 process and its application in delivering an anticancer drug to treat cancer cells are also successfu

276 iodistribution of intravenously administered anticancer drugs to bone.

277 The direct use of anticancer drugs to create their own nanostructures is a

278 owever, the overlapping toxicity of multiple anticancer drugs to healthy tissues and increasing finan

279 Nanoparticles are used to deliver anticancer drugs to solid tumors.

280 BCB1 and ABCG2 limit the exposure of several anticancer drugs to the brain, leading to suboptimal tre

281 xorubicin (DOX) is one of the most effective anticancer drugs to treat various forms of cancers; howe

282 ystem to optimize the delivery efficiency of anticancer drugs to tumors.

283 compared to the clinically used camptothecin anticancer drugs topotecan and irinotecan.

284 and high-resolution complexes of GP with the anticancer drug toremifene and the painkiller ibuprofen.

285 ared wafers releasing Temozolomide (TMZ), an anticancer drug used systemically for treating GBM.

286 can be used to improve therapeutic index of anticancer drugs used for PC treatment.

287 he feasibility and benefits of delivering an anticancer drug using a carrier-free nanoparticle formul

288 and a hydroxamic acid, which is found in the anticancer drug vorinostat (SAHA).

289 Doxorubicin (DOX), a widely used clinical anticancer drug, was conveniently loaded into nanocarrie

290 Using 5 common anticancer drugs, we exemplified detection of differenti

291 Cisplatin is a widely prescribed anticancer drug, which triggers cell death by covalent b

292 lay superior anticancer efficacy over parent anticancer drugs, which are often approved products.

293 target for the development of several useful anticancer drugs, which compromise rapidly dividing cell

294 eciation of oocyte response to radiation and anticancer drugs will uncover new targets for the develo

295 acid coated nanocrystals of camptothecin, an anticancer drug with poor aqueous solubility and stabili

296 hioguanine and dasatinib are three important anticancer drugs with high adverse effects in human body

297 g of research directed to development of new anticancer drugs with novel mechanisms of action.

298 ere, we used this assay to rank 62 different anticancer drugs with respect to their effects on chromo

299 Combination of anticancer drugs with therapeutic microRNA (miRNA) has e

300 Topoisomerase II (TOP2) poisons as anticancer drugs work by trapping TOP2 cleavage complexe